what changed for me between month 11 and month 20
The title is the whole question — what changed for me between month 11 and month 20 — but here is why I am asking. Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board. The diabetes…
Right, and the diabetes programmes report glycaemic endpoints. Quoting an obesity trial result here is answering a different question.
Incretin-based agents stimulate insulin secretion in a glucose-dependent manner, which is why hypoglycaemia risk with them alone is low. Risk rises with agents that act independently of glycaemia.
That A1c change is inside the assay’s variability and the interval you measured over is too short.
the diabetes trials report different endpoints from the obesity ones
Not convinced. Hypoglycaemia risk from this class alone is low; the risk you are describing comes from the combination.
That is a sensor value, not a plasma value, and the two are not interchangeable at that level of precision.
Brought the whole CGM export to my appointment rather than one number. Entirely different conversation.
sensor accuracy varies and the first day of a sensor is the worst